Treatment of the Pediatric Patient with An Inborn Error of Metabolism
Updates in Treatment of Neuromuscular Disease (SMA, DMD)
Updates to Pediatric Gastrointestinal Disorders: IBD and SBS

• Series Overview
• Program Content
• Faculty
• Financial Relationship Disclosures
• Target Audience and Learning Objectives
• Continuing Pharmacy Education Credit
• BCPPS Specialty Recertification Credit
• Technical Requirements
• Commercial Support
• Fees

Clinical Reasoning Series in Pediatric Pharmacy has been approved by the Board of Pharmacy Specialties (BPS) as one component of the professional development programs developed by ACCP for recertification of the Board Certified Pediatric Pharmacy Specialist (BCPPS).

This educational series explores cutting-edge, contemporary therapeutic topics and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants' skills and abilities to critically evaluate the scientific evidence and effectively incorporate significant findings into daily practice that lead to effective and safe patient care.

The program will consist of several educational activities and is presented in three parts with each part containing:

• streaming audio/slide synchronized presentations
• downloadable mp3 audio files
• downloadable mp4 video files
• downloadable/printable PDFs of presentation slides
• Continuing Pharmacy Education (CPE) credit
• Recertification Credit - Available with Specialty Recertification package.

Release date: December 12, 2023
BCPPS credit expiration date: December 12, 2024
ACPE credit expiration date: December 12, 2026

Treatment of the Pediatric Patient with An Inborn Error of Metabolism

Pediatric patients with inborn errors of metabolism are rare in the general pediatric population. Therefore, pediatric pharmacists may not be familiar with acute and chronic management strategies. This session is designed to provide knowledge of evidence-based acute and chronic management strategies. Program attendees will gain knowledge of treatment goals, preparedness in cases of metabolic emergencies, and recent FDA-approved medications for pediatric patients with inborn errors of metabolism, as well as the skills needed to implement this information into their own practice.

This program will explore the following topics:

• Evidence-based therapeutic strategies and goals of care
• Develop strategies to improve institutional preparedness for pediatric metabolic emergencies
• Medications with recent FDA-approvals

Updates in Treatment of Neuromuscular Disease (SMA, DMD)

This education program aims to provide pediatric pharmacists with the knowledge and tools to provide care to pediatric patients with neuromuscular disorders. The pathophysiology of three neuromuscular disorders, spinal muscular atrophy (SMA), Friedreich Ataxia (FA), and Duchenne muscular dystrophy (DMD) will be provided. Given the complexity of these disorders, patients may require hospitalization, and knowledge of the disease states, goals of treatment, and pharmacological management is necessary for the inpatient pediatric pharmacist and for use in the outpatient pediatric pharmacy setting.

This program will explore the following topics:

• Pathophysiology of Spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and Friedreich's ataxia (FA)
• Risk factors for medication side effects
• Treatment and monitoring plans

Updates to Pediatric Gastrointestinal Disorders: IBD and SBS

Currently, pediatric pharmacists encounter pediatric patients with gastrointestinal disorders across all areas of healthcare practice (e.g., inpatient, ambulatory, transitions of care). The etiology of short bowel syndrome (SBS) is secondary to numerous conditions that require resection of the small intestine. Acute and chronic management is based on the amount of remaining small bowel and understanding the resulting dysfunction. Inflammatory bowel disease (IBD) is comprised of two disorders: ulcerative colitis (UC) and Crohn's disease (CD). These patients are often emergently admitted prior to diagnosis and require chronic management in the ambulatory setting. Clinicians who may not routinely take care of pediatric patients with SBS and IBD may not be aware of best practice strategies and new pharmacological agents. This education program aims to provide inpatient and outpatient pediatric pharmacists with the knowledge and tools to care for pediatric patients with Short Bowel Syndrome and Inflammatory Bowel Disease.

This program will explore the following topics:

• The functions of the gastrointestinal organs
• Pharmacokinetic differences in patients with Short Bowel Syndrome (SBS)
• Developing pharmacologic management strategies
• Pathophysiology of Inflammatory Bowel Disease (IBD) and patient presentation based on disease type
• The role and integration of biologic therapy in the management of IBD

Clinical Reasoning Series in Pediatric Pharmacy – Program Chair

	Ingrid Pan, Pharm.D., BCPPS Pediatric Ambulatory Rheumatology Pharmacist Children's Hospital Colorado Aurora, Colorado

Treatment of the Pediatric Patient with An Inborn Error of Metabolism

	Ellie G. Hendricks, Pharm.D., BCPPS Clinical Staff Pharmacist - Critical Care Float Children's Hospital Colorado Aurora, Colorado

Updates in Treatment of Neuromuscular Disease (SMA, DMD):

	Rachel V. Kinn, Pharm.D., BCPPS Clinical Pharmacy Specialist, Pediatric Neurology University of Iowa Hospitals and Clinics Iowa City, Iowa

Updates to Pediatric Gastrointestinal Disorders: IBD and SBS

	Malia Swan Kleespies, Pharm.D., BCPPS Clinical Pharmacy Specialist – Pediatric Hospital Medicine University of Chicago Medicine, Comer Children's Hospital Chicago, Illinois

We thank the following peer reviewers for lending their time and expertise to this Clinical Reasoning Series in Pediatric Pharmacy.

Financial Relationship Disclosures

Disclosures 

TARGET AUDIENCE
The target audience for the Clinical Reasoning Series in Pediatric Pharmacy is the pharmacist practicing in a clinical setting as a Board Certified Pediatric Pharmacy Specialist (BCPPS) looking to earn rectification credit and those clinicians seeking additional information on the topics covered.

LEARNING OBJECTIVES
Treatment of the Pediatric Patient with An Inborn Error of Metabolism:

1. Define initial goals of care for the pediatric patient with concern for a metabolic emergency.
2. Recommend evidence-based therapeutic strategies to achieve initial goals of care.
3. Develop strategies to improve institutional preparedness for pediatric metabolic emergencies.
4. Recommend evidence-based therapeutic strategies for chronic management of pediatric patients with inborn errors of metabolism.
5. Describe the clinical impact of medications with recent FDA-approvals for use in children with inborn errors of metabolism.

Updates in Treatment of Neuromuscular Disease (SMA, DMD):

1. Describe the pathophysiology of Spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and Friedreich's ataxia (FA).
2. Determine goals of treatment and response to medication therapy for neuromuscular patients.
3. Analyze risk factors for medication side effects in the treatment of pediatric patients with neuromuscular disorders.
4. Develop an SMA treatment and monitoring plan based on patient specific factors and wishes.

Updates to Pediatric Gastrointestinal Disorders: IBD and SBS:

1. Examine the functions of the gastrointestinal organs.
2. Analyze the differences of pharmacokinetics in patients with Short Bowel Syndrome (SBS).
3. Determine appropriate pharmacologic management strategies for complications of Short Bowel Syndrome.
4. Distinguish the pathophysiology of Inflammatory Bowel Disease (IBD) and patient presentation based on disease type.
5. Develop a therapeutic plan with monitoring parameters to manage Inflammatory Bowel Disease in a pediatric patient using guidelines and consensus management strategies.
6. Evaluate the current literature for the role and integration of biologic therapy in the management of pediatric Inflammatory Bowel Disease.

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Treatment of the Pediatric Patient with An Inborn Error of Metabolism

Activity Number: 0217-0000-23-099-H01-P
Contact Hours: 2.00
Activity Type: Application-Based Activity

Updates in Treatment of Neuromuscular Disease (SMA, DMD)

Activity Number: 0217-0000-23-100-H01-P
Contact Hours: 2.00
Activity Type: Application-Based Activity

Updates to Pediatric Gastrointestinal Disorders: IBD and SBS

Activity Number: 0217-0000-23-101-H01-P
Contact Hours: 2.00
Activity Type: Application-Based Activity

Methods and CE Requirements

ACPE Continuing Pharmacy Education Credit
Activities consist of audio/video/PDF files, attestation statements, and activity evaluations. Learners must purchase the product, review all content, and complete the attestation statements and course evaluations to receive continuing pharmacy education credit for each activity. You must submit the attestation statements and course evaluations associated with each activity within the course by December 12, 2026.

National Association of Boards of Pharmacy - CPE Monitor Service

Provided through the collaborative efforts of the National Association of Boards of Pharmacy (NABP), the Accreditation Council for Pharmacy Education (ACPE), and ACPE-accredited providers, the CPE Monitor Service allows you to electronically keep track of continuing pharmacy education (CPE) credits from ACPE-accredited providers. ACPE-accredited providers, like ACCP, are responsible for transmitting this information to NABP to be stored in the CPE Monitor system. Statements of credit will be available at CPE Monitor, nabp.pharmacy/cpe-monitor-service/, within 2–3 business days after completion of this activity. For more information on CPE Monitor please visit nabp.pharmacy/cpe-monitor-service/.

To transfer these credits to CPE Monitor on your behalf your NABP e-Profile ID Number and date of birth must be listed on your ACCP account. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Some international pharmacists do not use the CPE Monitor service. To verify or update this information in your ACCP account, visit Licensure/Certification. Check the box “I am an international pharmacist or I am not licensed to practice in the United States, and do not have an NABP e-Profile ID.” Be sure to save your changes at the bottom of the page.

To be eligible to earn BCPPS recertification credit, participants must purchase the recertification version of this course, review all content, successfully complete, submit and pass the Web-based posttest associated with each activity by December 12, 2024. You are allowed only one attempt to successfully complete this assessment.

The passing point to earn BCPPS recertification credit is based on an expert analysis of the assessment items in each posttest activity. Any posttest submitted before the BCPPS posttest deadline that meets this passing point will earn BCPPS recertification credits. These credits will be assigned as of the date of test submission. For statements of recertification credit, visit www.bpsweb.org.

All participants must have a Board of Pharmacy Specialties (BPS) board certification credential number, BPS ID Number, and a BPS expiration date on file with ACCP for reporting purposes. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Questions regarding the number of hours required for BCPPS recertification should be directed to BPS at (202) 946-5026 or www.bpsweb.org. The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs.

• Internet browser
• Adobe Reader (available free)

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.